title: Alcon
id: 2338581
Alcon Inc German Alcon AG is a Swiss American pharmaceutical and medical device company specializing in eye care products It has a paper headquarters in Geneva Switzerland but its operational headquarters are in Fort Worth Texas United States where it employs about people br Alcon was a subsidiary of Novartis until April when it was spun out into a separate publicly traded company Alcon itself has a number of subsidiaries including Aerie Pharmaceuticals focused on therapies for glaucoma and other diseases of the eye and WaveLight which develops and manufactures laser eye surgery technologies br br br History br Alcon was founded in as a small pharmacy in Fort Worth Texas United States It was named for its founders pharmacists Robert Alexander and William Conner who focused on sterile ophthalmic products br Nestl of Switzerland purchased Alcon in Alcon expanded its manufacturing capability with new plants in South America and Europe and drastically increased its investment in research br In Alcon acquired Texas Pharmacal Company which became Dermatological Products of Texas and is now DPT Laboratories br In Alcon founded the Technical Excellence Award to promote achievements in R D excellence and has awarded it to more than recipients The Alcon product line has expanded from pharmaceuticals to the surgical arena Today Alcon has operations in countries and its products are sold in over countries br Nestl conducted an initial public offering of of its stake in Alcon in The stock is traded under the ticker symbol ALC In July Novartis purchased approximately of Nestl s stake in Alcon with an option to buy Nestl s remaining shares beginning in Novartis bought stake from Nestl for Billion This deal brought the total ownership of Alcon by Novartis to Beginning January Novartis formally announced it will be completing the exercise options for finishing purchasing the rest of Alcon and then promptly continue to exercise merger and takeover of Alcon br On March Alcon acquired Durezol and Zyclorin from Sirion Therapeutics Alcon received regulatory approval to acquire the rights of Durezol emulsion in the US and the global rights excluding Latin America for Zyclorin from Sirion Therapeutics br On June Alcon s Independent Director Committee announced that a recommendation by the committee was an indispensable first step before the board of the company can decide on the merger proposal of Novartis AG refuted Novartis public implications that it would be able to unilaterally impose the merger irrespective of the Independent Director Committee s position once Novartis became Alcon s majority shareholder On July Alcon s independent director committee IDC had set up a million litigation trust to ensure company s minority shareholders get the best deal from bidder Novartis AG br On April Alcon completed a spin off from Novartis The new standalone company is worth up to billion Swiss francs br In November Alcon announced it would acquire Ivantis and their glaucoma surgery stent technology for at least million In August Alcon agreed to buy Aerie Pharmaceuticals for US million to enhance its ophthalmic pharmaceutical portfolio br br br br br br External links br br Business data for Alcon br Alcon Official Website br Alcon Novartis exercises option and proposes merger br Novartis needs Alcon directors OK for buyout br Swiss Corporate Governance Expert Supports Alcon Independent Director Committee s Position against Novartis